(lp0
S'MabVax Therapeutics Holdings, Inc. Has a Promising Pancreatic Cancer Treatment Equities.com - Oct 17, 2016 At the end of the second quarter this year, biotech junior MabVax Therapeutics Holdings, Inc.  enacted a 1-for-7.4 reverse split of its common stock and uplisted to the Nasdaq Capital Market.'
p1
aS'MabVax Therapeutics Holdings Inc. MBVX  Wall Street Journal - Oct 11, 2014 MabVax Therapeutics Holdings Inc. MBVX . search. View All companies. AT CLOSE 4:00 PM EST 03/10/17. $2.87 USD; 0.16 5.90%. Volume 77,157. Volume 77,157. 65 Day Avg Vol 61,667. 1 Day Range 2.68 - 2.8852. 52 Week Range 2.5138&nbsp;...'
p2
aS'Opko Spots Another Overlooked Opportunity In MabVax Therapeutics Seeking Alpha - Apr 8, 2015 Opko Health has a strong track record of identifying undervalued companies in which to invest. Opko most recently announced a strategic investment in MabVax Therapeutics which appears to present another such investment opportunity. MabVax has a&nbsp;...MabVax Therapeutics Catches Eye of Billionaire Investor Dr. Phillip Frost and ... - Marketwired '
p3
aS'MabVax Therapeutics Holdings Hires Paul Resnick, MD as Chief Business Officer PR Newswire  - Apr 15, 2016 SAN DIEGO, April 15, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. , a clinical-stage oncology drug development company, announces the hiring of Paul Resnick, M.D.'
p4
aS'Telik and MabVax Therapeutics Announce Definitive Merger Agreement PR Newswire  - May 12, 2014 Upon the closing of the transaction, Telik will be re-named MabVax Therapeutics Holdings, Inc. and will operate under the leadership of the MabVax management team with J. David Hansen, President and CEO of MabVax, serving as the President, CEO, and&nbsp;...Cancer Drug Developers MabVax, Telik Merge - Genetic Engineering NewsWhy Telik  Stock Is Soaring Today - TheStreet.com'
p5
aS"MabVax Therapeutics Receives Stockholder Approval for Name Change and Reverse ... PR Newswire  - Sep 9, 2014 SAN DIEGO, Sept. 9, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. , a publicly-traded clinical stage cancer immunotherapy company, announced today that stockholders have approved a change in the Company's name from&nbsp;..."
p6
aS"MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You? Seeking Alpha - Apr 14, 2015 A recent press release* lists MBVX's market cap at just $18 Mil. This number is misleading. Shares have taken off since it was announced that Dr."
p7
aS"MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer ... PR Newswire  - May 19, 2016 SAN DIEGO, May 19, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. , a clinical-stage immuno-oncology drug development company, announces that Paul Maffuid, PhD, Executive Vice President of Research and Development,&nbsp;..."
p8
aS'MabVax Therapeutics Announces Closing of Financing PR Newswire  - Apr 6, 2015 SAN DIEGO, April 6, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.  , a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6&nbsp;...All Hail to MABVAX THERAPEUTICS  - MicroCap Daily'
p9
aS"MabVax Therapeutics Holdings, Inc.  Reaches $2.57 1 Year Low; Exactech ... Wolcott Daily - Mar 16, 2017 The stock of MabVax Therapeutics Holdings, Inc.  hit a new 52-week low and has $2.44 target or 5.00% below today's $2.57 share price."
p10
a.